Literature DB >> 8920699

Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.

A Lees1, B L Nelson, J J Mond.   

Abstract

Neonates have poor immune responses to type 2 T-cell independent antigens (TI-2), such as polysaccharides and immunization of human infants with these antigens does not induce protective levels of serum antibodies. Conjugating proteins to TI-2 antigens converts the immune response to one which is T-cell dependent. We used an organic cyanylating reagent, 1-cyano-4-dimethylaminopyridinium tetrafluroborate (CDAP), to activate polysaccharides, in water, and subsequently react them with hexanediamine, in preparation for coupling proteins to the polysaccharide. CDAP activation of polysaccharide is rapid (< 2 min) and efficient. CDAP can be used to activate polysaccharides of diverse chemical natures, including dextrans and pneumococcal types 6, 14, 19 and 23. The critical parameters in CDAP activation of polysaccharides were the reagent concentrations and the pH. Activation can be performed over a broad alkaline pH range, with an optimum of pH 9-10. Furthermore, proteins can be coupled to CDAP-activated polysaccharides without the use of a spacer. Direct conjugation of protein to CDAP-activated polysaccharides can be performed under mildly alkaline conditions (pH 7-9). These conditions allow CDAP to be used with alkaline-sensitive polysaccharides and proteins. Mice immunized with BSA-pneumococcal type 14 polysaccharides (Pn14) conjugates, prepared either by direct conjugation or via a spacer, had high anti-Pn14 and anti-BSA serum antibody IgG1 titers, whereas no IgG1 antibody was induced to the unconjugated components. The ease of use and mild activating conditions should prove of value in using CDAP to prepare conjugate vaccines, as well as other immunologically useful reagents.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920699     DOI: 10.1016/0264-410x(95)00195-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

1.  Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Authors:  Ying-Jie Lu; Ian Chr Skovsted; Claudette M Thompson; Porter W Anderson; Richard Malley
Journal:  Microb Pathog       Date:  2009-07-03       Impact factor: 3.738

2.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

3.  Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Authors:  Jan Poolman; Carl Frasch; Anu Nurkka; Helena Käyhty; Ralph Biemans; Lode Schuerman
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

4.  Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae.

Authors:  Elizabeth Diago-Navarro; Isabel Calatayud-Baselga; Donglei Sun; Camille Khairallah; Inderjit Mann; Amaia Ulacia-Hernando; Brian Sheridan; Meiqing Shi; Bettina C Fries
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

6.  Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.

Authors:  E Konadu; A Donohue-Rolfe; S B Calderwood; V Pozsgay; J Shiloach; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.

Authors:  Tomás Maira-Litrán; Andrea Kropec; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Authors:  Margret Y Richter; Håvard Jakobsen; Alda Birgisdottir; Jean-François Haeuw; Ultan F Power; Giuseppe Del Giudice; Antonella Bartoloni; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  (18)F-Labeling of Mannan for Inflammation Research with Positron Emission Tomography.

Authors:  Xiang-Guo Li; Cecilia Hagert; Riikka Siitonen; Helena Virtanen; Outi Sareila; Heidi Liljenbäck; Jouni Tuisku; Juhani Knuuti; Jörgen Bergman; Rikard Holmdahl; Anne Roivainen
Journal:  ACS Med Chem Lett       Date:  2016-05-16       Impact factor: 4.345

10.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.